Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) is projected to issue its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $7.50 million for the quarter. Parties can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 14, 2026 at 12:30 PM ET.
Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last posted its quarterly earnings results on Wednesday, March 11th. The company reported ($0.12) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.12). On average, analysts expect Tenaya Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Tenaya Therapeutics Trading Down 4.5%
NASDAQ TNYA opened at $0.75 on Wednesday. Tenaya Therapeutics has a 1-year low of $0.36 and a 1-year high of $2.35. The company has a market capitalization of $163.68 million, a PE ratio of -1.22 and a beta of 2.77. The firm's fifty day simple moving average is $0.72 and its 200-day simple moving average is $0.93.
Analyst Ratings Changes
Several equities analysts recently weighed in on the stock. Leerink Partners reaffirmed an "outperform" rating and set a $2.00 price objective on shares of Tenaya Therapeutics in a research report on Thursday, March 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Tenaya Therapeutics in a research note on Wednesday, January 21st. William Blair reaffirmed an "outperform" rating on shares of Tenaya Therapeutics in a research note on Thursday, March 12th. Chardan Capital reaffirmed a "buy" rating and issued a $8.00 price objective on shares of Tenaya Therapeutics in a research note on Thursday, March 12th. Finally, Lifesci Capital raised shares of Tenaya Therapeutics to a "strong-buy" rating in a research note on Thursday, March 5th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $4.00.
View Our Latest Report on TNYA
Insider Activity
In related news, major shareholder Group Gp Lp Column III sold 3,511,826 shares of Tenaya Therapeutics stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $0.56, for a total value of $1,966,622.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have sold 8,594,047 shares of company stock valued at $5,430,207. 48.65% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Tenaya Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Scientech Research LLC acquired a new position in Tenaya Therapeutics during the third quarter valued at approximately $27,000. Geode Capital Management LLC grew its holdings in Tenaya Therapeutics by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 1,193,355 shares of the company's stock valued at $849,000 after purchasing an additional 17,820 shares during the last quarter. Cetera Investment Advisers raised its holdings in Tenaya Therapeutics by 107.0% in the 4th quarter. Cetera Investment Advisers now owns 106,425 shares of the company's stock worth $76,000 after acquiring an additional 55,000 shares during the period. Jefferies Financial Group Inc. bought a new position in Tenaya Therapeutics in the 3rd quarter worth $99,000. Finally, Comerica Bank bought a new position in Tenaya Therapeutics in the 1st quarter worth $50,000. Institutional investors and hedge funds own 90.54% of the company's stock.
Tenaya Therapeutics Company Profile
(
Get Free Report)
Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.
Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tenaya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenaya Therapeutics wasn't on the list.
While Tenaya Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
